{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:41:19Z","timestamp":1793040079837,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2007,6,2]],"date-time":"2007-06-02T00:00:00Z","timestamp":1180742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/2.0"},{"start":{"date-parts":[[2007,6,2]],"date-time":"2007-06-02T00:00:00Z","timestamp":1180742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/2.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2007,11]]},"DOI":"10.1007\/s00259-007-0457-7","type":"journal-article","created":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T10:26:21Z","timestamp":1180693581000},"page":"1854-1860","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidney"],"prefix":"10.1007","volume":"34","author":[{"given":"Edgar J.","family":"Rolleman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter P. M.","family":"Kooij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter W.","family":"de Herder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roelf","family":"Valkema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric P.","family":"Krenning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,6,2]]},"reference":[{"key":"457_CR1","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1053\/snuc\/2002.31025","volume":"32","author":"R Valkema","year":"2002","unstructured":"Valkema R, De Jong M, Bakker WH, Breeman WA, Kooij PP, Lugtenburg PJ, et al. Phase I study of peptide receptor radionuclide therapy with [111In-DPTA0]octreotide: the Rotterdam experience. Semin Nucl Med 2002;32:110\u201322.","journal-title":"Semin Nucl Med"},{"key":"457_CR2","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s002590050476","volume":"26","author":"A Otte","year":"1999","unstructured":"Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 1999;26:1439\u201347.","journal-title":"Eur J Nucl Med"},{"key":"457_CR3","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00259-002-1050-8","volume":"30","author":"DJ Kwekkeboom","year":"2003","unstructured":"Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJ, Kooij PP, de Herder WW, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate. Eur J Nucl Med Mol Imaging 2003;30:417\u201322.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"457_CR4","first-page":"62S","volume":"46","author":"DJ Kwekkeboom","year":"2005","unstructured":"Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005;46:62S\u20136S.","journal-title":"J Nucl Med"},{"key":"457_CR5","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1053\/snuc.2002.31565","volume":"32","author":"I Virgolini","year":"2002","unstructured":"Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G, Riva P. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med 2002;32:148\u201355.","journal-title":"Semin Nucl Med"},{"key":"457_CR6","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1007\/s00259-004-1571-4","volume":"31","author":"L Bodei","year":"2004","unstructured":"Bodei L, Cremonesi M, Grana C, Rocca P, Bartolomei M, Chinol M, et al. Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2004;31:1038\u201346.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"457_CR7","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0360-3016(91)90171-Y","volume":"21","author":"B Emami","year":"1991","unstructured":"Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991;21:109\u201322.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"457_CR8","first-page":"83S","volume":"46","author":"R Valkema","year":"2005","unstructured":"Valkema R, Pauwels SA, Kvols LK, Kwekkeboom DJ, Jamar F, de Jong M, et al. Long-term follow-up of renal function after peptide receptor radiation therapy with 90Y-DOTA0,Tyr3-Octreotide and 177Lu-DOTA0, Tyr3-Octreotate. J Nucl Med 2005;46:83S\u201391S.","journal-title":"J Nucl Med"},{"key":"457_CR9","first-page":"99S","volume":"46","author":"R Barone","year":"2005","unstructured":"Barone R, Borson-Chazot F, Valkema R, Walrand S, Chauvin F, Gogou L, et al. Patient-specific dosimetry in predicting renal toxicity with 90Y-DOTATOC: Relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med 2005;46:99S\u2013106S.","journal-title":"J Nucl Med"},{"key":"457_CR10","first-page":"1388","volume":"37","author":"M De Jong","year":"1996","unstructured":"De Jong M, Rolleman EJ, Bernard BF, Visser TJ, Bakker WH, Breeman WA, et al. Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo. J Nucl Med 1996;37:1388\u201392.","journal-title":"J Nucl Med"},{"key":"457_CR11","first-page":"709","volume":"45","author":"EJ Rolleman","year":"2004","unstructured":"Rolleman EJ, Krenning EP, Van Gameren A, Bernard BF, De Jong M. Uptake of [111In-DTPA0]octreotide in the rat kidney is inhibited by colchicine and not by fructose. J Nucl Med 2004;45:709\u201313.","journal-title":"J Nucl Med"},{"key":"457_CR12","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/bjc.1993.266","volume":"67","author":"PJ Hammond","year":"1993","unstructured":"Hammond PJ, Wade AF, Gwilliam ME, Peters AM, Myers MJ, Gilbey SG, et al. Amino acid infusion blocks renal tubular uptake of an indium-labelled somatostatin analogue. Br J Cancer 1993;67:1437\u20139.","journal-title":"Br J Cancer"},{"key":"457_CR13","first-page":"3825","volume":"55","author":"TM Behr","year":"1995","unstructured":"Behr TM, Sharkey RM, Juweid ME, Blumenthal RD, Dunn RM, Griffiths GL, et al. Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res 1995;55:3825\u201334.","journal-title":"Cancer Res"},{"key":"457_CR14","first-page":"1929","volume":"38","author":"BF Bernard","year":"1997","unstructured":"Bernard BF, Krenning EP, Breeman WA, Rolleman EJ, Bakker WH, Visser TJ, et al. D-Lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake. J Nucl Med 1997;38:1929\u201333.","journal-title":"J Nucl Med"},{"key":"457_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00259-002-0982-3","volume":"30","author":"EJ Rolleman","year":"2003","unstructured":"Rolleman EJ, Valkema R, De Jong M, Kooij PP, Krenning EP. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging 2003;30:9\u201315.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"457_CR16","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1093\/ndt\/gfh362","volume":"19","author":"R Barone","year":"2004","unstructured":"Barone R, Pauwels S, De Camps J, Krenning EP, Kvols LK, Smith MC, et al. Metabolic effects of amino acid solutions infused for renal protection during therapy with radiolabelled somatostatin analogues. Nephrol Dial Transplant 2004;19:2275\u201381.","journal-title":"Nephrol Dial Transplant"},{"key":"457_CR17","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s00259-003-1117-1","volume":"30","author":"F Jamar","year":"2003","unstructured":"Jamar F, Barone R, Mathieu I, Walrand S, Labar D, Carlier P, et al. 86Y-DOTA0-d-Phe1-Tyr3-octreotide (SMT487)\u2014a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging 2003;30:510\u20138.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"457_CR18","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1111\/j.1523-1755.2005.00160.x","volume":"67","author":"R Barone","year":"2005","unstructured":"Barone R, Van Der Smissen P, Devuyst O, Beaujean V, Pauwels S, Courtoy PJ, et al. Endocytosis of the somatostatin analogue, octreotide, by the proximal tubule-derived opossum kidney (OK) cell line. Kidney Int 2005;67:969\u201376.","journal-title":"Kidney Int"},{"key":"457_CR19","first-page":"1696","volume":"46","author":"M De Jong","year":"2005","unstructured":"De Jong M, Barone R, Krenning E, Bernard B, Melis M, Visser T, et al. Megalin is essential for renal proximal tubule reabsorption of 111In-DTPA-octreotide. J Nucl Med 2005;46:1696\u2013700.","journal-title":"J Nucl Med"},{"key":"457_CR20","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1210\/jc.77.5.1323","volume":"77","author":"JC Reubi","year":"1993","unstructured":"Reubi JC, Horisberger U, Studer UE, Waser B, Laissue JA. Human kidney as target for somatostatin: high affinity receptors in tubules and vasa recta. J Clin Endocrinol Metab 1993;77:1323\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"457_CR21","doi-asserted-by":"crossref","first-page":"F457","DOI":"10.1152\/ajprenal.2001.280.3.F457","volume":"280","author":"DA Balster","year":"2001","unstructured":"Balster DA, O\u2019Dorisio MS, Summers MA, Turman MA. Segmental expression of somatostatin receptor subtypes sst(1) and sst(2) in tubules and glomeruli of human kidney. Am J Physiol Renal Physiol 2001;280:F457\u201365.","journal-title":"Am J Physiol Renal Physiol"},{"key":"457_CR22","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1007\/BF00181765","volume":"20","author":"EP Krenning","year":"1993","unstructured":"Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716\u201331.","journal-title":"Eur J Nucl Med"},{"key":"457_CR23","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1016\/0024-3205(91)90053-E","volume":"49","author":"WH Bakker","year":"1991","unstructured":"Bakker WH, Krenning EP, Reubi JC, Breeman WA, Setyono-Han B, de Jong M, et al. In vivo application of [111In-DTPA-D-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in rats. Life Sci 1991;49:1593\u2013601.","journal-title":"Life Sci"},{"key":"457_CR24","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3109\/00365517709101835","volume":"37","author":"CE Mogensen","year":"1977","unstructured":"Mogensen CE, Solling. Studies on renal tubular protein reabsorption: partial and near complete inhibition by certain amino acids. Scand J Clin Lab Invest 1977;37:477\u201386.","journal-title":"Scand J Clin Lab Invest"},{"key":"457_CR25","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1001\/jama.265.7.888","volume":"265","author":"O Serri","year":"1991","unstructured":"Serri O, Beauregard H, Brazeau P, Abribat T, Lambert J, Harris A, et al. Somatostatin analogue, octreotide, reduces increased glomerular filtration rate and kidney size in insulin-dependent diabetes. JAMA 1991;265:888\u201392.","journal-title":"JAMA"},{"key":"457_CR26","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s001250051585","volume":"44","author":"A Luksch","year":"2001","unstructured":"Luksch A, Polak K, Matulla B, Dallinger S, Kapiotis S, Rainer G, et al. Glucose and insulin exert additive ocular and renal vasodilator effects on healthy humans. Diabetologia 2001;44:95\u2013103.","journal-title":"Diabetologia"},{"key":"457_CR27","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1046\/j.1523-1755.2002.00320.x","volume":"61","author":"A Schmidt","year":"2002","unstructured":"Schmidt A, Pleiner J, Schaller G, Roden M, Dallinger S, Mayer G, et al. Renal hemodynamic effects of somatostatin are not related to inhibition of endogenous insulin release. Kidney Int 2002;61:1788\u201393.","journal-title":"Kidney Int"},{"key":"457_CR28","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/BF01649420","volume":"69","author":"T Tulassay","year":"1991","unstructured":"Tulassay T, Tulassay Z, Rascher W, Szucs L, Seyberth HW, Nagy I. Effect of somatostatin on kidney function and vasoactive hormone systems in health subjects. Klin Wochenschr 1991;69:486\u201390.","journal-title":"Klin Wochenschr"},{"key":"457_CR29","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1210\/jcem-64-5-975","volume":"64","author":"J Vora","year":"1987","unstructured":"Vora J, Owens DR, Luzio S, Atiea J, Ryder R, Hayes TM. Renal response to intravenous somatostatin in insulin-dependent diabetic patients and normal subjects. J Clin Endocrinol Metab 1987;64:975\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"457_CR30","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.1365-2362.1992.tb01496.x","volume":"22","author":"RP Dullaart","year":"1992","unstructured":"Dullaart RP, Meijer S, Marbach P, Sluiter WJ. Effect of a somatostatin analogue, octreotide, on renal haemodynamics and albuminuria in acromegalic patients. Eur J Clin Invest 1992;22:494\u2013502.","journal-title":"Eur J Clin Invest"},{"key":"457_CR31","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/j.1572-0241.2005.40899.x","volume":"100","author":"G Kalambokis","year":"2005","unstructured":"Kalambokis G, Economou M, Fotopoulos A, Al Bokharhii J, Pappas C, Katsaraki A, et al. The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites. Am J Gastroenterol 2005;100:879\u201385.","journal-title":"Am J Gastroenterol"},{"key":"457_CR32","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1093\/ndt\/gfh871","volume":"20","author":"G Kalambokis","year":"2005","unstructured":"Kalambokis G, Economou M, Fotopoulos A, Bokharhii JA, Katsaraki A, Tsianos EV. Renal effects of treatment with diuretics, octreotide or both, in non-azotemic cirrhotic patients with ascites. Nephrol Dial Transplant 2005;20:1623\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"457_CR33","first-page":"F444","volume":"255","author":"P Castellino","year":"1988","unstructured":"Castellino P, Giordano C, Perna A, DeFronzo RA. Effects of plasma amino acid and hormone levels on renal hemodynamics in humans. Am J Physiol 1988;255:F444\u20139.","journal-title":"Am J Physiol"},{"key":"457_CR34","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1055\/s-2007-1004971","volume":"22","author":"Z Tulassay","year":"1990","unstructured":"Tulassay Z, Tulassay T, Szucs L, Nagy I. Effects of long acting somatostatin analogue on renal functions. Horm Metab Res 1990;22:555\u20136.","journal-title":"Horm Metab Res"},{"key":"457_CR35","first-page":"309","volume":"28","author":"M Krempf","year":"1990","unstructured":"Krempf M, Ranganathan S, Remy JP, Charbonnel B, Guillon J. Effect of long-acting somatostatin analog (SMS 201\u2013995) on high glomerular filtration rate in insulin dependent diabetic patients. Int J Clin Pharmacol Ther Toxicol 1990;28:309\u201311.","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"457_CR36","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S0168-8278(97)80247-4","volume":"26","author":"A Malesci","year":"1997","unstructured":"Malesci A, Tacconi M, Valentini A, Basilico M, Lorenzano E, Salerno F. Octreotide long-term treatment in patients with portal hypertension: persistent inhibition of postprandial glucagon response without major changes in renal function. J Hepatol 1997;26:816\u201325.","journal-title":"J Hepatol"},{"key":"457_CR37","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/j.1523-1755.2005.00395.x","volume":"68","author":"P Ruggenenti","year":"2005","unstructured":"Ruggenenti P, Remuzzi A, Ondei P, Fasolini G, Antiga L, Ene-Iordache B, et al. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int 2005;68:206\u201316.","journal-title":"Kidney Int"},{"key":"457_CR38","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1023\/A:1026698001921","volume":"43","author":"M Sabat","year":"1998","unstructured":"Sabat M, Guarner C, Soriano G, Bulbena O, Novella MT, Ortiz J, et al. Effect of subcutaneous administration of octreotide on endogenous vasoactive systems and renal function in cirrhotic patients with ascites. Dig Dis Sci 1998;43:2184\u20139.","journal-title":"Dig Dis Sci"},{"key":"457_CR39","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/j.1365-2362.1992.tb01506.x","volume":"22","author":"RP Dullaart","year":"1992","unstructured":"Dullaart RP, Meijer S, Marbach P, Sluiter WJ. Renal reserve filtration capacity in growth hormone deficient subjects. Eur J Clin Invest 1992;22:562\u20138.","journal-title":"Eur J Clin Invest"},{"key":"457_CR40","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1093\/oxfordjournals.ndt.a091713","volume":"3","author":"T Mountokalakis","year":"1988","unstructured":"Mountokalakis T, Kallivretakis N, Mayopoulou-Symvoulidou D, Karvountzis G, Tolis G. Enhancement of renal function by a long-acting somatostatin analogue in patients with decompensated cirrhosis. Nephrol Dial Transplant 1988;3:604\u20137.","journal-title":"Nephrol Dial Transplant"},{"key":"457_CR41","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1053\/jhep.2001.26754","volume":"34","author":"LH Ottesen","year":"2001","unstructured":"Ottesen LH, Aagaard NK, Kiszka-Kanowitz M, Rehling M, Henriksen JH, Pedersen EB, et al. Effects of a long-acting formulation of octreotide on renal function and renal sodium handling in cirrhotic patients with portal hypertension: a randomized, double-blind, controlled trial. Hepatology 2001;34:471\u20137.","journal-title":"Hepatology"},{"key":"457_CR42","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1053\/jhep.2003.50276","volume":"38","author":"G Pomier-Layrargues","year":"2003","unstructured":"Pomier-Layrargues G, Paquin SC, Hassoun Z, Lafortune M, Tran A. Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study. Hepatology 2003;38:238\u201343.","journal-title":"Hepatology"},{"key":"457_CR43","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/BF00209003","volume":"20","author":"U Dorr","year":"1993","unstructured":"Dorr U, Rath U, Sautter-Bihl ML, Guzman G, Bach D, Adrian HJ, et al. Improved visualization of carcinoid liver metastases by indium-111 pentetreotide scintigraphy following treatment with cold somatostatin analogue. Eur J Nucl Med 1993;20:431\u20133.","journal-title":"Eur J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-007-0457-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-007-0457-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-007-0457-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-007-0457-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T19:15:08Z","timestamp":1630437308000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-007-0457-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,2]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2007,11]]}},"alternative-id":["457"],"URL":"https:\/\/doi.org\/10.1007\/s00259-007-0457-7","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,2]]},"assertion":[{"value":"21 January 2007","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2007","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2007","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}